While the gist of Delic’s near term revenue generation strategy is fairly simple, how the team got to be in the position to execute it is not. It took vision, foresight and years of building out the framework to be ready for these opportunities. Again, such vision and foresight are defining attributes of the leadership of young microcap companies that go on to find huge success.
This is venture investing. We’re betting on this team to create value with our capital. The Delic team didn’t just put their hands out and ask for a truck load of cash. They raised just enough to go out and leverage their expertise and bootstrap VALUE for shareholders. Of the 54 millions shares outstanding over 35 million (including the team’s shares) have been locked up. This demonstrates significant commitment to shareholders and self-confidence in their ability to create value.
In the past two decades, though, the FDA, U.S. Drug Enforcement Administration, and other governments’ regulators have been quietly easing barriers to research, and scientists are once again finding therapeutic uses for the drugs. These findings are leading to increasing numbers of clinical drug trials that could help bring these psychedelics to market as legal pharmaceutical drugs.
